B
Bosco Paes
Researcher at McMaster University
Publications - 263
Citations - 8149
Bosco Paes is an academic researcher from McMaster University. The author has contributed to research in topics: Palivizumab & Intensive care. The author has an hindex of 43, co-authored 252 publications receiving 7427 citations. Previous affiliations of Bosco Paes include Umm al-Qura University & Stanford University.
Papers
More filters
Journal ArticleDOI
Development of the human coagulation system in the full-term infant
Maureen Andrew,Bosco Paes,Ruth Milner,Marilyn F. M. Johnston,Marilyn F. M. Johnston,Lesley Mitchell,Lesley Mitchell,Douglas M. Tollefsen,Peter Powers,Peter Powers +9 more
TL;DR: A large cohort of infants studied consecutively in the postnatal period allowed us to determine the normal development of the human coagulation system in the full-term infant and found that near-adult values are achieved for most components by 6 months of life.
Journal ArticleDOI
Development of the human coagulation system in the healthy premature infant
Maureen Andrew,Bosco Paes,Ruth Milner,Marilyn Johnston,Lesley Mitchell,Douglas M. Tollefsen,Valerie Castle,Peter Powers +7 more
TL;DR: The postnatal maturation towards adult levels was accelerated in premature infants as compared with the fullterm infants and with adults.
Journal ArticleDOI
Development of the hemostatic system in the neonate and young infant.
TL;DR: Current understanding of the protein components of the coagulation and fibrinolytic systems in the neonate is reviewed, which resulted in a better appreciation of the development of the hemostatic system in the infant.
Journal ArticleDOI
The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
Barbara J. Law,Joanne M. Langley,Upton Allen,Bosco Paes,David S. C. Lee,Ian Mitchell,John S. Sampalis,Hervé Walti,Joan L. Robinson,Karel O'Brien,Carina Majaesic,Georges Caouette,Lyne Frenette,Nicole Le Saux,Brian S. Simmons,Sharon E. Moisiuk,Koravanagattu Sankaran,Cecil Ojah,Avash J. Singh,Marc H. Lebel,Godfrey S. Bacheyie,Heather Onyett,Andrea F. Michaliszyn,Patricia Manzi,Diana Parison +24 more
TL;DR: Specific host/environmental factors can be used to identify which 33-35GA infants are at greatest risk of hospitalization for RSV infection and likely to benefit from palivizumab prophylaxis.
Journal ArticleDOI
Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries
Louis Bont,Paul A. Checchia,Brigitte Fauroux,Josep Figueras-Aloy,Paolo Manzoni,Bosco Paes,Eric A. F. Simões,Xavier Carbonell-Estrany +7 more
TL;DR: RSV infection remains a major burden on Western healthcare systems and has been associated with significant morbidity and associated risk factors, so further studies are needed to determine the true burden of disease.